Rapport Therapeutics (RAPP) Director Sanchez Buys $98K of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) director Ramiro Sanchez purchased 3,600 shares of the clinical-stage biopharmaceutical company on October 23, 2026. According to an SEC Form 4 filing, the shares were acquired at a price of $27.35 each, totaling approximately $98,477.64. Following this transaction, the director holds a total of 3,600 shares in the company.

RAPP Rapport Therapeutics, Inc.

$26.53 ▼ -5.62% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Inside Ramiro Sanchez's RAPP Trade

The purchase took place on October 23, 2026, with the shares acquired in the open market under direct ownership. On the day of the trade, Rapport Therapeutics stock closed at $25.93. The transaction was not executed under a pre-arranged Rule 10b5-1 trading plan.

Other Institutional Activity in Rapport Therapeutics

Other major institutional investors have adjusted their positions in the stock during recent periods. Trv Gp V, LLC reduced its holdings by 854,814 shares, ending with 6,280,525 shares worth about $162,854,015. Arch Venture Management, Llc kept its stake steady at 3,728,738 shares valued at roughly $96,686,177. Capital International Investors trimmed its position by 175,962 shares to hold 2,921,958 shares worth approximately $75,766,371. Cormorant Asset Management, LP cut its holdings by 299,881 shares, finishing with 2,657,521 shares valued at about $68,909,520. Meanwhile, Sofinnova Investments, Inc. maintained its position at 1,904,408 shares worth roughly $49,381,300.

Rapport Therapeutics, Inc. Stock Up 3.5%

RAPP recently traded around $26.53 as of October 23, 2026, which is up about 2.3% from its event-day close of $25.93. The shares have traded between a 52-week low of $23.75 and a 52-week high of $52.93.

Recent Earnings

Rapport Therapeutics reported trailing-twelve-month revenue of $20.0 million and earnings per share of -$3.03. The company holds a return on equity of -40.0% and net margin of 0.0%. Its next corporate earnings release is scheduled for November 5, 2026.

Insider Buying and Selling at Rapport Therapeutics, Inc.

Several other board members executed purchases prior to this trade. Director John Maraganore bought 9,411 shares on October 22, 2026, at an average price of $26.45 for a total of $248,890.83. Director Steven M Paul picked up 35,714 shares on October 22, 2026, at $27.28 per share worth $974,277.92. Director Wendy B. Young acquired 3,789 shares on October 22, 2026, at $26.39 per share totaling $99,991.71. Director Paul M Silva bought 3,680 shares on October 22, 2026, at an average of $27.07 for $99,636.00.

Analysts Set New Price Targets

Analyst firms updated their views on the stock ahead of the filing. On October 20, 2026, HC Wainwright & Co. reiterated a buy rating with a $66.00 price target. BTIG maintained a buy rating on October 20, 2026, while raising its price target to $89.00 from $75.00. Jones Trading maintained a buy rating on October 21, 2026, and lifted its price target to $82.00 from $50.00. Wells Fargo maintained an overweight rating on October 21, 2026, adjusting its target to $50.00 from $51.00. Guggenheim maintained a buy rating on October 21, 2026, raising its target to $70.00 from $65.00. Overall, the stock carries a consensus recommendation key of strong_buy from 15 analyst opinions.

About Rapport Therapeutics

Headquartered in Boston, Massachusetts, Rapport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and developing small molecule medicines for central nervous system disorders. The firm employs 84 people and maintains a market capitalization of approximately $1.27 billion.

Bottom Line

Investors tracking Rapport Therapeutics will look toward the upcoming earnings report on November 5, 2026, for further financial updates. Form 4 filings will continue to provide visibility into any additional insider transactions from directors and executives.